HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $7.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective decreased by HC Wainwright from $8.00 to $7.00 in a research note published on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.87 on Friday. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The stock has a market capitalization of $108.12 million, a price-to-earnings ratio of -0.68 and a beta of 0.25. The business has a 50-day moving average of $1.04 and a 200-day moving average of $1.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $33.13 million for the quarter, compared to analyst estimates of $35.02 million. On average, sell-side analysts expect that Karyopharm Therapeutics will post -1.25 EPS for the current year.

Insider Activity

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 360,744 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $1.00, for a total transaction of $360,744.00. Following the completion of the transaction, the director now directly owns 11,209 shares in the company, valued at $11,209. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 1,282,902 shares of company stock worth $1,244,993. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KPTI. Bleakley Financial Group LLC bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $33,000. Simplicity Solutions LLC bought a new stake in Karyopharm Therapeutics during the fourth quarter valued at $33,000. SG Americas Securities LLC boosted its position in Karyopharm Therapeutics by 295.0% during the fourth quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after acquiring an additional 54,839 shares during the last quarter. Simplicity Wealth LLC acquired a new position in shares of Karyopharm Therapeutics during the first quarter valued at about $66,000. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Karyopharm Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 115,864 shares of the company’s stock valued at $100,000 after purchasing an additional 29,380 shares during the period. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).